Protocol No
MIRATI-1719-001
Phase
I/II
Summary
This project is being done to determine how much MRTX1719 can safely be administered
to people.
Description
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
ClinicalTrials.gov